MedTrace Logo

Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China

NCT01928836 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 764

Last updated 2015-05-27

No results posted yet for this study

Summary

The purpose of this study is to verify clinical utility of a simple blood test comprising of four protein- based markers for risk stratification of patients presenting symptoms related to lung cancer.

Conditions

  • Lung Neoplasms

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Nanjing PLA General Hospital

    collaborator OTHER

  • Third Military Medical University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Bai Chunxue

    lead OTHER

Principal Investigators

  • Chunxue Bai, Prof. · Chinese Alliance Against Lung Cancer

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-01-31
Completion
2015-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928836 on ClinicalTrials.gov